TABLE 2B.
CSF Findings in POST–COVID‐19 Patients
| Case | CSF Lymphocytes, μl | Total CSF Protein, g/l | Anti–SARS‐CoV‐2 IgG | AISARS‐CoV‐2 | SARS‐CoV‐2 RNA (E or N gene), Ct Value | |
|---|---|---|---|---|---|---|
| CSF | Serum | |||||
| Post–COVID‐19 | ||||||
| Case 21 | 0 | 0.42 | Not det. | Not det. | — | Not det. |
| Case 22 | 3 | 0.19 | Not det. | 1,182.71 | — | Not det. |
| Case 23 | 1 | 0.25 | 47.76 | 25,994.37 | 1.15 | 38.20 a |
| Case 24 | 5 | 0.36 | 5.74 | 1,983.64 | 0.77 | Not det. |
| Case 25 | 7 | 0.36 | 8.95 | 3,916.38 | 0.86 | Not det. |
| Case 26 | 1 | 0.24 | 3.59 | 2,340.37 | 0.97 | Not det. |
| Case 27 | 2 | 0.26 | 3.88 | 6,233.72 | 0.20 | Not det. |
| Case 28 | 2 | 0.28 | Not det. | Not det. | — | Not det. |
| Case 29 | 1 | 0.33 | 7.69 | 3,975.46 | 0.80 | Not det. |
| Case 30 | 1 | 0.16 | 2.35 | 1,600.14 | 1.40 | Not det. |
| Case 31 | 4 | 0.33 | 6.40 | 3,244.73 | 0.80 | Not det. |
| Case 32 | 4 | 0.55 | 23.50 | 6,144.03 | 0.77 | Not det. |
| Case 33 | 0 | 0.31 | 13.23 | 5,984.96 | 1.02 | Not det. |
| Case 34 | 0 | 0.26 | Not det. | 121.71 | — | Not det. |
| Case 35 | 1 | 0.22 | 10.99 | 11,228.37 | 0.55 | Not det. |
| Case 36 | 0 | 0.39 | 7.41 | 4,023.44 | 0.94 | Not det. |
| Case 37 | 2 | 0.29 | Not det. | Not det. | — | Not det. |
| Case 38 | 1 | 0.25 | Not det. | 739.52 | — | Not det. |
| Case 39 | 8 | 0.41 | 4.63 | 1,598.22 | 0.78 | Not det. |
| Case 40 | 1 | 0.21 | 17.32 | 13,146.16 | 0.95 | Not det. |
| Median (range) | 1.00 (0–8) | 0.29 (0.16–0.55) | 7.55 (2,35–47.76) | 3,916.38 (121.71–25,994.37) | 0.83 (0.20–1.40) | |
Oligoclonal band status was available in 33 of the 40 patients and 17 of the 20 patients with post–COVID19 syndrome, with none of the patients showing type 2 or 3 oligoclonal bands suggestive of intrathecally produced antibodies.
a
Not confirmed using alternative polymerase chain reaction protocols; for details, see Materials and Methods section.
AI = antibody index; CSF = cerebrospinal fluid; Ct = cycle threshold; IgG = immunoglobulin class G; Not det. = not detected.